References - Clinical Applications of Saccharomyces boulardii

McFarland, L., Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology : WJG, 2010. 16: p. 2202-22.
Kelesidis, T. and C. Pothoulakis, Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 2012. 5: p. 111-25.
Buts, J.-P., Twenty-Five Years of Research on Saccharomyces boulardii Trophic Effects: Updates and Perspectives. Digestive Diseases and Sciences, 2008. 54: p. 15-8.
Buts, J.-P. and N. Keyser, Effects of Saccharomyces boulardii on Intestinal Mucosa. Digestive Diseases and Sciences, 2006. 51: p. 1485-92.
Breves, G., et al., Application of the Colon-Simulation Technique for Studying the Effects of Saccharomyces boulardii on Basic Parameters of Porcine Cecal Microbial Metabolism Disturbed by Clindamycin. Digestion, 2000. 61: p. 193-200.
Schneider, S., et al., Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology : WJG, 2005. 11: p. 6165-9.
More, M. and A. Swidsinski, Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal Gropper, S., J. Smith, and T. Carr, Advanced Nutrition and Human Metabolism. 7th ed. 2017, Boston, MA: Cengage Learning.
Berni Canani, R., et al., Saccharomyces boulardii: A summary of the evidence for gastroenterology clinical practice in adults and children. European Review for Medical and Pharmacological Sciences, 2011. 15: p. 809-22.
Stier, H. and S.C. Bischoff, [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system]. MMW Fortschritte der Medizin, 2017. 159(Suppl 5): p. 1-6.
Czerucka, D. and P. Rampal, Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World Journal of Gastroenterology, 2019. 25: p. 2188-2203.
Fidan, I., et al., Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses, 2009. 52: p. 29-34.
Myllyluoma, E., et al., Effects of Multispecies Probiotic Combination on Helicobacter pylori Infection In Vitro. Clinical and vaccine immunology : CVI, 2008. 15: p. 1472-82.
Gropper, S., J. Smith, and T. Carr, Advanced Nutrition and Human Metabolism. 7th ed. 2017, Boston, MA: Cengage Learning.
Sun, J., Vitamin D and mucosal immune function. Curr Opin Gastroenterol, 2010. 26(6): p. 591-5.
Braun, L. and M. Cohen, Herbs & Natural Supplements: An Evidence-Based Guide. 4th ed. 2015, Sydney: Churchill Livingstone/Elsevier.
Bikle, D., Nonclassic Actions of Vitamin D. J Clin Endocrinol Metab, 2008. 94(1): p. 26-34.
Roy, S.K., et al., Impact of zinc supplementation on intestinal permeability in Bangladeshi children with acute diarrhoea and persistent diarrhoea syndrome. Journal of Pediatric Gastroenterology and Nutrition, 1992. 15(3): p. 289-296.
Rahman, M.J., et al., Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis. The American Journal Of Clinical Nutrition, 2005. 81(2): p. 495-502.
Szajewska, H. and M. Kołodziej, Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 2015. 42.
Kollaritsch, H., et al., [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med, 1993. 111(9): p. 152-156.
Kollaritsch, H., et al., Prevention of traveller's Prevention of traveller's diarrhea: diarrhea: Comparison of different non-antibiotic Comparison of different non-antibiotic preparations preparations. Travel Med Int, 1989. 11.
Szajewska, H., M. Kołodziej, and B. Zalewski, Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update. Alimentary Pharmacology & Therapeutics, 2020. 51.
Abbas, Z., et al., Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. European Journal of Gastroenterology & Hepatology, 2014. 26.
Guslandi, M., P. Giollo, and P. Testoni, A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology & Hepatology, 2003. 15: p. 697-8.
Zhou, B.G., et al., Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis. Helicobacter, 2019. 24(5): p. e12651.
Dinleyici, E., et al., Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitology Research, 2010. 108(3): p. 541-5.
Besirbellioglu, A., et al., Saccharomyces boulardii and infection due to Giardia lamblia. Scandinavian journal of infectious diseases, 2006. 38: p. 479-81.
Buts, J.P., M. Corthier G Fau - Delmee, and M. Delmee, Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr. 16(4): p. 419-25.
Villar, J., et al., Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS One, 2017. 12: p. e0173802.
García-Collinot, G., et al., Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Digestive Diseases and Sciences, 2020. 65(4): p. 1134-43.